FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.
What happened
FDA inspected Empower Clinic Services, LLC dba Empower Pharmacy in Houston, TX, from November 3, 2025, through November 14, 2025, and issued a Form FDA 483 (inspection observations) on November 14, 2025. FDA collected evidence that the firm compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products that appeared to be essentially copies of FDA-approved semaglutide and tirzepatide, regularly and in inordinate amounts, with prescription records lacking individualized prescriber determinations of significant difference. FDA also observed sterile production under insanitary conditions and violations of current good manufacturing practice (CGMP), the required manufacturing quality standards, including inadequate smoke studies and media fills and inconsistent media fill records.
What FDA found
The company compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products that appeared to be essentially copies of FDA-approved semaglutide and tirzepatide, regularly and in inordinate amounts, so they did not qualify for the section 503A exemptions (limited exceptions for compounded drugs).
FD&C Act §§ 503A(b)(1)(D), 503A(b)(2) [21 U.S.C. §§ 353a(b)(1)(D), 353a(b)(2)]The company marketed these compounded drugs without FDA-approved new drug applications.
FD&C Act §§ 505(a), 301(d) [21 U.S.C. §§ 355(a), 331(d)]Sterile drug products were prepared under insanitary conditions because smoke studies did not adequately show unidirectional airflow in the ISO 5 area.
FD&C Act § 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Media fills were not performed under the most challenging or stressful conditions, so there was insufficient assurance of aseptic production.
FD&C Act § 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm failed to establish and follow written procedures to prevent microbiological contamination of sterile drug products, including validation of aseptic and sterilization processes.
21 CFR 211.113(b)The quality control unit failed to ensure drug products complied with CGMP and met specifications for identity, strength, quality, and purity.
21 CFR 211.22
What FDA wants
Within 15 working days of receipt, notify FDA in writing of the specific steps taken to address the violations, explain how recurrence will be prevented, and include related documentation; if the company cannot fully address the matter in that time, it must state why and give a timeframe. FDA also strongly recommends a comprehensive management assessment of operations, especially aseptic processing, with a third-party consultant who has sterile drug manufacturing expertise.
Who should pay attention
- clinics and prescribers ordering compounded semaglutide or tirzepatide
- patients using compounded semaglutide or tirzepatide injections
- other pharmacies making sterile compounded drugs
This is a summary. Read the original letter on fda.gov.